Editas Medicine
EDIT
99 hedge funds and large institutions have $614M invested in Editas Medicine in 2017 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 15 closing their positions.
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
88% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 17
61% more capital invested
Capital invested by funds: $381M → $614M (+$233M)
18% more funds holding
Funds holding: 84 → 99 (+15)
3.54% more ownership
Funds ownership: 64.09% → 67.63% (+3.5%)
31% less call options, than puts
Call options by funds: $5.38M | Put options by funds: $7.75M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
Capital World Investors
Los Angeles,
California
|
+$30.6M |
| 2 |
BlackRock
New York
|
+$23.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8M |
| 4 |
Millennium Management
New York
|
+$11.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.35M |
Top Sellers
EDIT Hedge Fund Activity: Q1 2017 in Review
99 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2017, worth a combined $614M — up 61% from $381M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new EDIT positions and 15 closed out — a net gain of 20 holders — while 32 added to existing stakes and 17 trimmed.
The largest buyer was Capital World Investors, adding an estimated $30.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10.2M sold.
- 99 institutional investors held Editas Medicine (EDIT) as of Q1 2017, up from 84 in Q4 2016.
- Funds reported $614M of Editas Medicine stock for Q1 2017, up 61% quarter-over-quarter.
- 35 funds opened new Editas Medicine positions in Q1 2017 and 15 closed out, a net change of +20 holders.
- The largest Editas Medicine buyer in Q1 2017 was Capital World Investors, an estimated $30.6M added.
- The largest Editas Medicine seller in Q1 2017 was EcoR1 Capital, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2017.